Opthea Q&A Sep 2024 Update, page-34

Can anyone square the circle for these two statements by OPT

"Securing close to US$300 million through successful
financings mid-2023 (US$58 million), in December 2023
(US$85 million) and mid‑2024 (US$152 million) is expected
to fund the Company’s operations through topline data
readout of bothglobal pivotal trials and the completion of
commercial‑scale manufacturing to support sozinibercept’s
anticipated Biologics License Application (BLA) filing in
the US. "

For me that means further CR until both toplines and preparing commerical labs for at scale production .

and this statement

"Note: Additional funding will be required to reach commercialization of sozinibercept and to meet obligations under the Development Funding Agreement ("DFA"). As a result of obligations under the DFA and applicable law regarding liquidity, the Company expects tor raise or obtain additional capital in one or more transactions,earlier than 3Q CY 2025 or anticipated topline data readout dates. "

Which for me means, well we will need more money in Q1,Q2 2025 or even topline data readout. For me these statements cannot both true.